Join
Live feed
·
PRReleasevia Quantisnow
Intensity Therapeutics Inc. logo

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

ByQuantisnow·Wall Street's wire, on your screen.
INTS· Intensity Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INTS (Intensity Therapeutics Inc.) and more on Quantisnow.